Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials

BACKGROUND AND OBJECTIVES: Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation. Benzodiazepines represent a drug class associated with drug-facilitated sexual assaults, espe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pesic, Marija, Stöhr, Thomas, Ossig, Joachim, Borkett, Keith, Donsbach, Martin, Dao, Van-Anh, Webster, Lynn, Schippers, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419402/
https://www.ncbi.nlm.nih.gov/pubmed/32757149
http://dx.doi.org/10.1007/s40268-020-00317-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419402/
https://www.ncbi.nlm.nih.gov/pubmed/32757149
http://dx.doi.org/10.1007/s40268-020-00317-0

Ejemplares similares